HOTH
HOTH company profile
Latest price
As of — · Market data by Massive
Market cap
—
Volume
—
Previous close
—
Day range
—
Listed
—
Coverage
6 articles
Price performance
Recent trading
Newsroom
Latest HOTH coverage
Pre-Market Movers: 6/6/2023
Hoth Therapeutics Inc. (HOTH) is experiencing a significant surge in the Pre-Market session with a substantial gain of 83.6%. The company's stock is currently trading at $3.45 with a considerable trading volume of around 5,879,000 shares. Recruiter.com Group Inc. (RCRT) is having a robust Pre-Market session, with its shares appreciating by 40.7%. The stock i
Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results – Reduce Amyloid β in Alzheimer’s Disease
Significant decrease in Aβ after acute treatment with HT-ALZ, supporting that HT-ALZ has the potential to modify Aβ plaque formation in the brain NEW YORK, NY January 4, 2022/PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using a Alzheimer’s disease mouse model
Hoth Therapeutics Announces Submission of Orphan Designation Application for HT-KIT to Treat Mastocytosis
NEW YORK, NY December 21, 2021 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH) a patient-focused clinical-stage biopharmaceutical company, announced it submitted an Orphan Drug Designation Application to the US Food and Drug Administration (FDA) for HT-KIT for the treatment of mastocyctosis. HT-KIT is an antisense oligonucleotide that targets the proto-
Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics
Hoth to receive shares in Zylö and potential future sales royalties NEW YORK, NY December 8, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that it has entered into an agreement with Zylö Therapeutics (“Zylö”)
Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT
NEW YORK, NY November 16, 2021/PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has signed a Sponsored Research Agreement with North Carolina State University (“NC State”) to support the continued research and development of HT-KIT, a novel therapeutic for the treatment mast cell cance
Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans
NEW YORK, NY October 12, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence cohort 2 of the Phase 1 clinical trial of BioLexa Lotion for the treatment of mild to moderate atopic dermatitis in Australia. BioLexa Trial Design: